In vitro longitudinal relaxivity profile of Gd (ABE-DTTA), an investigational magnetic resonance imaging contrast agent

Akos Varga-Szemes, Pal Kiss, Andras Rab, Pal Suranyi, Zsofia Lenkey, T. Símor, Robert G. Bryant, Gabriel A. Elgavish

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: MRI contrast agents (CA) whose contrast enhancement remains relatively high even at the higher end of the magnetic field strength range would be desirable. The purpose of this work was to demonstrate such a desired magnetic field dependency of the longitudinal relaxivity for an experimental MRI CA, Gd(ABE-DTTA). Materials and Methods: The relaxivity of 0.5mM and 1mM Gd(ABE-DTTA) was measured by Nuclear Magnetic Relaxation Dispersion (NMRD) in the range of 0.0002 to 1T. Two MRI and five NMR instruments were used to cover the range between 1.5 to 20T. Parallel measurement of a Gd-DTPA sample was performed throughout as reference. All measurements were carried out at 37°C and pH 7.4. Results: The relaxivity values of 0.5mM and 1mM Gd(ABE-DTTA) measured at 1.5, 3, and 7T, within the presently clinically relevant magnetic field range, were 15.3, 11.8, 12.4 s-1mM-1 and 18.1, 16.7, and 13.5 s-1mM-1, respectively. The control 4 mM Gd-DTPA relaxivities at the same magnetic fields were 3.6, 3.3, and 3.0 s-1mM-1, respectively. Conclusions: The longitudinal relaxivity of Gd(ABE-DTTA) measured within the presently clinically relevant field range is three to five times higher than that of most commercially available agents. Thus, Gd(ABE-DTTA) could be a practical choice at any field strength currently used in clinical imaging including those at the higher end.

Original languageEnglish
Article numbere0149260
JournalPLoS One
Volume11
Issue number2
DOIs
Publication statusPublished - Feb 1 2016

Fingerprint

Magnetic resonance
magnetic fields
magnetic resonance imaging
Contrast Media
Magnetic Fields
Magnetic Resonance Imaging
Imaging techniques
Magnetic resonance imaging
Magnetic fields
Gadolinium DTPA
Magnetic relaxation
Medical imaging
image analysis
Nuclear magnetic resonance
gadolinium N-(2-butyryloxyethyl)-N'-(2-ethyloxyethyl)-N,N'-bis(N'',N''-bis(carboxymethyl)acetamido)-1,2-ethanediamine
In Vitro Techniques
sampling
methodology

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

In vitro longitudinal relaxivity profile of Gd (ABE-DTTA), an investigational magnetic resonance imaging contrast agent. / Varga-Szemes, Akos; Kiss, Pal; Rab, Andras; Suranyi, Pal; Lenkey, Zsofia; Símor, T.; Bryant, Robert G.; Elgavish, Gabriel A.

In: PLoS One, Vol. 11, No. 2, e0149260, 01.02.2016.

Research output: Contribution to journalArticle

Varga-Szemes, Akos ; Kiss, Pal ; Rab, Andras ; Suranyi, Pal ; Lenkey, Zsofia ; Símor, T. ; Bryant, Robert G. ; Elgavish, Gabriel A. / In vitro longitudinal relaxivity profile of Gd (ABE-DTTA), an investigational magnetic resonance imaging contrast agent. In: PLoS One. 2016 ; Vol. 11, No. 2.
@article{fd36e4169bbd4279a29d4fa640eea370,
title = "In vitro longitudinal relaxivity profile of Gd (ABE-DTTA), an investigational magnetic resonance imaging contrast agent",
abstract = "Purpose: MRI contrast agents (CA) whose contrast enhancement remains relatively high even at the higher end of the magnetic field strength range would be desirable. The purpose of this work was to demonstrate such a desired magnetic field dependency of the longitudinal relaxivity for an experimental MRI CA, Gd(ABE-DTTA). Materials and Methods: The relaxivity of 0.5mM and 1mM Gd(ABE-DTTA) was measured by Nuclear Magnetic Relaxation Dispersion (NMRD) in the range of 0.0002 to 1T. Two MRI and five NMR instruments were used to cover the range between 1.5 to 20T. Parallel measurement of a Gd-DTPA sample was performed throughout as reference. All measurements were carried out at 37°C and pH 7.4. Results: The relaxivity values of 0.5mM and 1mM Gd(ABE-DTTA) measured at 1.5, 3, and 7T, within the presently clinically relevant magnetic field range, were 15.3, 11.8, 12.4 s-1mM-1 and 18.1, 16.7, and 13.5 s-1mM-1, respectively. The control 4 mM Gd-DTPA relaxivities at the same magnetic fields were 3.6, 3.3, and 3.0 s-1mM-1, respectively. Conclusions: The longitudinal relaxivity of Gd(ABE-DTTA) measured within the presently clinically relevant field range is three to five times higher than that of most commercially available agents. Thus, Gd(ABE-DTTA) could be a practical choice at any field strength currently used in clinical imaging including those at the higher end.",
author = "Akos Varga-Szemes and Pal Kiss and Andras Rab and Pal Suranyi and Zsofia Lenkey and T. S{\'i}mor and Bryant, {Robert G.} and Elgavish, {Gabriel A.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1371/journal.pone.0149260",
language = "English",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - In vitro longitudinal relaxivity profile of Gd (ABE-DTTA), an investigational magnetic resonance imaging contrast agent

AU - Varga-Szemes, Akos

AU - Kiss, Pal

AU - Rab, Andras

AU - Suranyi, Pal

AU - Lenkey, Zsofia

AU - Símor, T.

AU - Bryant, Robert G.

AU - Elgavish, Gabriel A.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Purpose: MRI contrast agents (CA) whose contrast enhancement remains relatively high even at the higher end of the magnetic field strength range would be desirable. The purpose of this work was to demonstrate such a desired magnetic field dependency of the longitudinal relaxivity for an experimental MRI CA, Gd(ABE-DTTA). Materials and Methods: The relaxivity of 0.5mM and 1mM Gd(ABE-DTTA) was measured by Nuclear Magnetic Relaxation Dispersion (NMRD) in the range of 0.0002 to 1T. Two MRI and five NMR instruments were used to cover the range between 1.5 to 20T. Parallel measurement of a Gd-DTPA sample was performed throughout as reference. All measurements were carried out at 37°C and pH 7.4. Results: The relaxivity values of 0.5mM and 1mM Gd(ABE-DTTA) measured at 1.5, 3, and 7T, within the presently clinically relevant magnetic field range, were 15.3, 11.8, 12.4 s-1mM-1 and 18.1, 16.7, and 13.5 s-1mM-1, respectively. The control 4 mM Gd-DTPA relaxivities at the same magnetic fields were 3.6, 3.3, and 3.0 s-1mM-1, respectively. Conclusions: The longitudinal relaxivity of Gd(ABE-DTTA) measured within the presently clinically relevant field range is three to five times higher than that of most commercially available agents. Thus, Gd(ABE-DTTA) could be a practical choice at any field strength currently used in clinical imaging including those at the higher end.

AB - Purpose: MRI contrast agents (CA) whose contrast enhancement remains relatively high even at the higher end of the magnetic field strength range would be desirable. The purpose of this work was to demonstrate such a desired magnetic field dependency of the longitudinal relaxivity for an experimental MRI CA, Gd(ABE-DTTA). Materials and Methods: The relaxivity of 0.5mM and 1mM Gd(ABE-DTTA) was measured by Nuclear Magnetic Relaxation Dispersion (NMRD) in the range of 0.0002 to 1T. Two MRI and five NMR instruments were used to cover the range between 1.5 to 20T. Parallel measurement of a Gd-DTPA sample was performed throughout as reference. All measurements were carried out at 37°C and pH 7.4. Results: The relaxivity values of 0.5mM and 1mM Gd(ABE-DTTA) measured at 1.5, 3, and 7T, within the presently clinically relevant magnetic field range, were 15.3, 11.8, 12.4 s-1mM-1 and 18.1, 16.7, and 13.5 s-1mM-1, respectively. The control 4 mM Gd-DTPA relaxivities at the same magnetic fields were 3.6, 3.3, and 3.0 s-1mM-1, respectively. Conclusions: The longitudinal relaxivity of Gd(ABE-DTTA) measured within the presently clinically relevant field range is three to five times higher than that of most commercially available agents. Thus, Gd(ABE-DTTA) could be a practical choice at any field strength currently used in clinical imaging including those at the higher end.

UR - http://www.scopus.com/inward/record.url?scp=84960538942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84960538942&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0149260

DO - 10.1371/journal.pone.0149260

M3 - Article

C2 - 26872055

AN - SCOPUS:84960538942

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e0149260

ER -